Blair William & Co. IL Sells 25,173 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Blair William & Co. IL decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 42.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 34,145 shares of the company’s stock after selling 25,173 shares during the period. Blair William & Co. IL’s holdings in Medpace were worth $11,344,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC grew its holdings in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after acquiring an additional 2,101 shares in the last quarter. Barclays PLC grew its stake in shares of Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after buying an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC raised its position in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after acquiring an additional 844 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Medpace by 10.0% in the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock valued at $14,722,000 after acquiring an additional 4,023 shares during the last quarter. Finally, SYM FINANCIAL Corp bought a new position in Medpace during the fourth quarter worth about $320,000. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on MEDP. Leerink Partners assumed coverage on Medpace in a research note on Monday, March 24th. They set a “market perform” rating and a $330.00 target price for the company. Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday, March 24th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $376.30.

Medpace Stock Down 1.3 %

NASDAQ MEDP opened at $312.36 on Friday. The firm has a 50-day moving average price of $335.90 and a two-hundred day moving average price of $339.07. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The company has a market capitalization of $9.52 billion, a P/E ratio of 24.73, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.